Biologics In Focus
Welcome to the October edition of “Biologics In Focus,” our monthly newsletter dedicated to the biologics industry.
As always, we’re excited to bring you comprehensive insights into the latest industry trends, expert perspectives, previews of upcoming events, and the newest updates from Lonza. This month, we’ll also share a captivating real-world customer story that highlights innovation and collaboration within our community.
If you find this month's edition enriching, consider joining our ever-expanding network of over 100K subscribers who receive our updates each month.
Lonza News and Updates
Read more about the successful completion of the expansion of our Drug Product Services (DPS) facility in Basel, Switzerland. This expansion enhances our capacity to provide end-to-end solutions, including drug formulation, clinical trial support, and commercial production. The upgraded facility aims to accelerate biopharmaceutical development and better serve clients’ growing demands for high-quality drug product manufacturing.
Insights and Analysis
Omics technologies are transforming CHO (Chinese Hamster Ovary) cell expression platforms for biologics production. Learn why genomics, transcriptomics, proteomics, and metabolomics are essential for improving cell line development, optimizing protein expression, and enhancing product quality. Discover the advantages of these advanced tools and how they are driving the development of next-generation, high-performing CHO platforms in biomanufacturing.
This white paper delves into the encapsulation of mRNA and nucleic acid-based therapeutics, exploring key challenges and solutions in the field. Explore the importance of lipid nanoparticle (LNP) technology for efficient delivery, the impact of particle size and formulation on therapeutic efficacy, and our capabilities in addressing these challenges.
Read about the crucial role that rapid toxicology material delivery plays in accelerating drug development. This article explores how fast, reliable access to toxicology materials shortens timelines for preclinical testing, helps meet regulatory requirements, and mitigates risks in drug development.
In this webinar, explore the latest additions to the GS® expression toolbox and strategies for using these technologies to drive successful development of your molecule from discovery to commercial supply. In addition, you’ll also hear about innovative methods for creating the next generation of cell expression systems.
Lonza in the Press
Learn about our collaboration with Acumen Pharmaceuticals to support the development of an early Alzheimer's disease treatment. By leveraging our expertise in biologics development and manufacturing, we’re helping advance ACU193, Acumen’s promising monoclonal antibody candidate. This partnership reinforces our commitment to delivering innovative solutions for neurodegenerative diseases and addressing critical unmet medical needs.
In the latest CDMO/CMO report, we’re proud to highlight Lonza’s leadership in the contract development and manufacturing space. Our comprehensive solutions, ranging from early drug development to commercial production, set us apart in the industry. By consistently investing in innovative technologies and expanding our global facilities, we continue to meet the evolving needs of our clients worldwide.
We’re excited to announce the completion of our microbial manufacturing expansion in Visp, Switzerland. This expansion increases our production capacity and strengthens our ability to deliver microbial-derived biopharmaceuticals. By enhancing our capabilities, we’re better positioned to meet the growing demand for microbial manufacturing, offering more flexibility and support for our customers' biologic and biotech product needs.
Customer Case Study
Hemogenyx Pharmaceuticals has utilized Lonza’s bYlok® bispecific pairing technology to develop an improved version of their CDX bispecific antibody candidate. The enhanced CDX molecule has demonstrated superior efficacy in in vitro testing. The customer is now conducting in vivo studies to evaluate its potential further. Hemogenyx representative emphasized the importance of this development. The improved CDX could potentially lead to better treatment outcomes for patients with blood cancers.
Key Upcoming Events
Upcoming Webinars
Thank you for reading. Remember to subscribe so you never miss our monthly updates.
If you'd like to find out more about Lonza Biologics, you can visit our website or contact one of our team of experts.